These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25208527)

  • 1. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
    Windschall D; Müller T; Becker I; Horneff G
    Rheumatol Int; 2015 Apr; 35(4):613-8. PubMed ID: 25208527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.
    Windschall D; Müller T; Becker I; Horneff G
    Clin Rheumatol; 2015 Jan; 34(1):61-9. PubMed ID: 25034081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
    Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
    Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Windschall D; Horneff G
    Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
    Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
    Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
    Raab A; Kallinich T; Huscher D; Foeldvari I; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner JB; Klein A; Horneff G
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):41. PubMed ID: 33752685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
    Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
    Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years.
    Tzaribachev N; Kuemmerle-Deschner J; Eichner M; Horneff G
    Rheumatol Int; 2008 Aug; 28(10):1031-4. PubMed ID: 18369626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
    Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
    Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
    Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
    Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
    Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
    Verazza S; Davì S; Consolaro A; Bovis F; Insalaco A; Magni-Manzoni S; Nicolai R; Marafon DP; De Benedetti F; Gerloni V; Pontikaki I; Rovelli F; Cimaz R; Marino A; Zulian F; Martini G; Pastore S; Sandrin C; Corona F; Torcoletti M; Conti G; Fede C; Barone P; Cattalini M; Cortis E; Breda L; Olivieri AN; Civino A; Podda R; Rigante D; La Torre F; D'Angelo G; Jorini M; Gallizzi R; Maggio MC; Consolini R; De Fanti A; Muratore V; Alpigiani MG; Ruperto N; Martini A; Ravelli A;
    Pediatr Rheumatol Online J; 2016 Dec; 14(1):68. PubMed ID: 27993144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
    Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.
    Constantin T; Foeldvari I; Vojinovic J; Horneff G; Burgos-Vargas R; Nikishina I; Akikusa JD; Avcin T; Chaitow J; Koskova E; Lauwerys BR; Calvo Penades I; Flato B; Gamir ML; Huppertz HI; Jaller Raad JJ; Jarosova K; Anton J; Macku M; Otero Escalante WJ; Rutkowska-Sak L; Trauzeddel R; Velez-Sanchez PJ; Wouters C; Wajdula J; Zang C; Bukowski J; Woodworth D; Vlahos B; Martini A; Ruperto N;
    J Rheumatol; 2016 Apr; 43(4):816-24. PubMed ID: 26932344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial.
    van Dijk BT; Bergstra SA; van den Berg JM; Schonenberg-Meinema D; van Suijlekom-Smit LWA; van Rossum MAJ; Koopman-Keemink Y; Ten Cate R; Allaart CF; Brinkman DMC; Hissink Muller PCE
    Pediatr Rheumatol Online J; 2024 May; 22(1):53. PubMed ID: 38730442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of etanercept for treatment of juvenile idiopathic arthritis: Results from a postmarketing surveillance.
    Mori M; Sugiyama N; Morishima Y; Sugiyama N; Kokubo T; Takei S; Yokota S
    Mod Rheumatol; 2018 Jan; 28(1):101-107. PubMed ID: 28448193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.
    Vojinović J; Foeldvari I; Dehoorne J; Panaviene V; Susic G; Horneff G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Akikusa J; Avcin T; Borlenghi C; Arthur E; Tatulych SY; Zang C; Tsekouras V; Vlahos B; Martini A; Ruperto N
    Rheumatology (Oxford); 2024 Jan; 63(1):140-148. PubMed ID: 37140539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.